KEY TAKEAWAYS

The False Binary That Breaks Teams

Leadership teams often believe they must choose. Be empathetic and risk unclear accountability. Or be accountable and risk appearing harsh. This binary is false. It persists because organizations have historically distorted both concepts. Accountability got weaponized into blame. Empathy got reduced to conflict avoidance. Kieran Engels has seen this dynamic destroy vendor relationships within weeks. A team that lacks empathy becomes a team that does not listen. A team that lacks accountability becomes a team with unclear expectations. The result: mutual frustration and escalating conflict.

The truth is: empathy is the precondition for clear accountability. If a vendor does not believe you understand their constraints, they will interpret accountability conversations as punishment. If they do not see empathy, they default to defensive postures. Similarly, if you are empathetic but never clarify what accountability looks like, you are being kind in the moment and cruel later, when misaligned expectations unravel the relationship.

What Empathy Really Means in Governance

Empathy in governance is not softness. It is clarity about context. It is understanding that your vendor has constraints you may not see. They have competing priorities from other clients. They have resource limitations. They have knowledge gaps about your program. Empathy means articulating these constraints explicitly so neither party misinterprets the other. It means asking why before assuming incompetence. It means understanding that when a vendor misses a deadline, the explanation matters because it informs how you course-correct.

Seuss+ builds governance that starts with empathy. Before you set expectations, understand what your vendor is working with. Before you hold them accountable, make sure you have given them the information they need to succeed. Before you escalate a miss, understand whether it is a capability gap or a resource allocation problem. These are not soft conversations. They are clear and direct. They prevent misinterpretation. They build trust.

What Accountability Really Means in Practice

Accountability is not punishment. It is clarity about consequences. It is defining upfront what will happen if expectations are not met. It is measuring progress against those expectations. It is giving feedback when performance drifts. It is following through when adjustments are needed. Accountability becomes harsh only when it arrives as a surprise. When it is expected and consistent, it is experienced as fair.

The core problem with many governance structures is distributed accountability. “We all own this.” “It is on all of us.” These statements sound collaborative and empathetic. They are actually the death of accountability. When everyone is accountable, no one is. When a program misses a milestone, unclear accountability means unclear corrective action. Vendors experience this as arbitrary. Sponsors experience this as evasion. Redesign accountability to be clear and specific. This vendor owns this deliverable. This sponsor leader owns this decision. This timeline is non-negotiable unless jointly agreed otherwise.

Three Scenarios: What Happens When You Get the Balance Right

Consider a scenario where a CRO misses an enrollment milestone. Without empathy, the response is punitive: escalate, audit, threaten replacement. The vendor becomes defensive. Collaboration ends. Enrollment actually slows because the vendor is protecting itself. With empathy alone, the response is understanding: “We get it, enrollment is hard. No worries. Let us adjust the timeline.” Expectations fade. The vendor has no incentive to course-correct. Timeline keeps slipping.

Now consider the third path: empathy and accountability working together. The conversation is direct but human. “We understand you are experiencing site recruitment challenges. That changes our view of the root cause but not our accountability expectation. We will adjust timeline by two weeks based on your revised recruitment plan. If that plan misses, we need to discuss replacement options. But we want to solve this together first.” The vendor is heard. But expectations are clear. This conversation is harder than either extreme. It is also the only one that builds sustainable relationships.

Three Approaches to Governance: Comparison

Key Industry Data

Retention improves measurably in organizations that invest in customized onboarding, mentorship programs, and inclusive leadership development. (Source: Industry retention analysis)

Senior executive turnover costs 213% of the departing leader’s annual salary when accounting for recruitment, onboarding, lost productivity, and institutional knowledge gaps. (Source: Leadership development research)

The cost to replace a specialized pharmaceutical or biotech professional ranges from 100% to 200% of annual salary, with senior roles exceeding $500,000 per replacement. (Source: Talent management research)

CRO voluntary separation rates have historically run at 12.5%, compared to a national average of 1.5% across industries. (Source: Industry benchmarks)

Pharmaceutical sales sector average annual turnover is 35%, with 44% of sales representatives leaving within their first two years. (Source: PharmExec)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Empathy and Accountability Are Not a Trade-Off: Building Governance That Works appeared first on Kieran Engels.

Key Takeaways

The Default Attribution Problem

When something fails in a clinical program, the first place people look is science. Did the drug work? Was the population right? Was the endpoint sensitive? These are important questions, but they are not the only questions.

The problem is that execution failure and scientific failure look similar from the outside. Both result in a program that does not work. But they require different solutions. If you misdiagnose, you will solve for the wrong problem and repeat the failure.

Where Execution Failure Lives

Execution failure happens in three places. Between intent and decision: leadership decides on a timeline without asking if vendors can deliver it. Between decision and delivery: a vendor understands the requirement differently than leadership intended. In delivery itself: unclear accountability means nobody catches the drift.

These failures are not bugs. They are features of systems that do not have clear governance.

Scientific Failure vs. Execution Failure

Building Systems to Prevent Misdiagnosis

The fix is not process. The fix is clarity. Before a program launches, document the intent. What are we trying to prove? What assumptions are we making? What happens if those assumptions break? Who is responsible for each decision? What are vendors committing to?

This documentation serves two purposes. First, it prevents execution failure by making intent explicit. Second, if failure happens anyway, it provides the diagnostic framework to distinguish execution failure from scientific failure.

Kieran Engels and Seuss+ work with biotech teams to build this diagnostic clarity through vendor governance and execution planning. Learn more at seuss.plus/about-us/.

Key Industry Data

FDA issued 303 warning letters in FY2025, a 59% increase from FY2024, with 135 directly based on inspection findings. (Source: FDA)

The most frequently cited inspection findings involve safety documentation delays, sponsor failure to monitor, and failure to select qualified monitors. (Source: EMA/FDA analysis)

Responses to Form 483 observations must be submitted within 15 business days. (Source: FDA)

The FDA issues Establishment Inspection Reports within 45 days of completing an inspection, and these become publicly available 3 to 6 months after the conclusion. (Source: FDA)

Inspection readiness planning should begin 6 to 12 months before regulatory submission to ensure all systems, documentation, and personnel are audit ready. (Source: Regulatory affairs guidance)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Failure Isn’t Always Scientific appeared first on Kieran Engels.

Key Takeaways

The Illusion of Speed

We have been taught to optimize for speed. Faster timelines. Faster decisions. Faster approval. But speed without control creates risk. A trial that moves fast but loses data integrity is not a success. A program that accelerates but loses track of what was promised is not progress. The illusion of speed comes from decoupling pace from accountability.

Accountability requires clarity. What are we committing to? Who is responsible if we miss? What are we assuming will go right? What is our contingency if assumptions break?

Execution Failure vs. Scientific Failure

When clinical programs fail, the default assumption is science. The drug did not work. The design was flawed. But many failures are execution failures. Poor handoffs between teams. Unclear accountability for decisions. Vendors operating without clear requirements. Requirements that vendors cannot actually meet.

What We Optimized For vs. What Accountability Requires

Building for Accountability

Accountability starts with clarity. What is the decision? Who made it? On what basis? What conditions would make us revisit it? These questions are not obstacles to speed. They are the foundation of confident speed.

Kieran Engels works with sponsors to build systems that embed accountability into governance. Not as punishment, but as clarity. When roles are explicit, decisions are documented, and assumptions are tested, teams move faster because they move with confidence.

Learn more about how Seuss+ helps teams build governance systems at seuss.plus/clinical-trial-vendor-optimization-services/.

Key Industry Data

The FDA formally adopted ICH E6(R3) on September 9, 2025, replacing the previous Good Clinical Practice framework with a risk based, proportionate oversight model. (Source: FDA)

The MHRA has classified ICH E6(R3) adoption as a major event in GCP, signaling that inspection criteria will shift toward Quality by Design assessment. (Source: MHRA)

Only 11.8% of drugs entering clinical testing ultimately receive regulatory approval, underscoring the cost of governance failures compounding scientific uncertainty. (Source: Tufts CSDD)

FDA warning letters surged 59% year over year in FY2025, from 190 to 303, reflecting heightened regulatory enforcement across the industry. (Source: FDA)

Trial delays cost sponsors $600,000 to $8 million per day, making accountability gaps not just a compliance risk but a direct financial exposure. (Source: Tufts CSDD)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post The Age of Accountability appeared first on Kieran Engels.